Gilead drops option to buy cancer therapeutics company


The reworked deal frees Gilead's South San Francisco partner to reach out to new sources of cash and collaborations.

Previous Moleculin enters Phase 2 clinical trials, reports bigger net loss in 2022 year-end results
Next Baptist Health, Encompass Health break ground on $44M hospital